Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 520-523

  Muto, Tomoya ^a,b   Sashida, Goro ^a,c   Hasegawa, Nagisa ^a,b   Nakaseko, Chiaki ^a,b   Yokote, Koutaro ^a   Shimoda, Kazuya ^d   Iwama, Atsushi ^a,c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; TET2 PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, MOUSE;

ANEMIA; BONE MARROW CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY FORMING UNIT GM; EXON; EXTRAMEDULLARY ERYTHROID HYPERPLASIA; EXTRAMEDULLARY HEMATOPOIESIS; HEMATOLOGICAL PARAMETERS; HYPERPLASIA; LETTER; LYMPHOCYTOPENIA; MONOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOID PROGENITOR CELL; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN DEPLETION; SPLENOMEGALY; THROMBOCYTOPENIA; ANIMAL; DEFICIENCY; ERYTHROID CELL; GENETICS; HEMATOPOIESIS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; SPLEEN; SURVIVAL ANALYSIS;

ANIMALS; DNA-BINDING PROTEINS; ERYTHROID CELLS; HEMATOPOIESIS; HEMATOPOIESIS, EXTRAMEDULLARY; HYPERPLASIA; MICE, KNOCKOUT; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; PROTO-ONCOGENE PROTEINS; SPLEEN; SURVIVAL ANALYSIS;

EID: 84923902194     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.924120     Document Type: Letter

References (12)

1. Sashida G, Iwama A. Epigenetic regulation of hematopoiesis. Int J Hematol 2012; 96: 405-412
2. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int J Hematol 2012; 96: 413-427
3. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-859
4. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612
5. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843
6. S hide K, Kameda T, Shimoda H, et al. T ET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012; 26: 2216-2223
7. M oran-Crusio K, Reavie L, Shih A, et al. T et2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24
8. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38
9. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518
10. M uto T, Sashida G, Oshima M, et al. C oncurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210: 2627-2639
11. Teff eri A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofi brosis. Leukemia 2009; 23: 905-911
12. B usque L, Patel J P, Figueroa M E, et al. R ecurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.